Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M 1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M 1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist.